ABT · News · 20260827N

Product Launch and Transition

ABBOTT LABORATORIES · 2026-08-27 · Importance 38 · Surprise 60

Abbott received CE Mark approval in Europe for its next-generation Amulet 360 Left Atrial Appendage Occluder. The device is designed for patients with non-valvular atrial fibrillation and seals the left atrial appendage to reduce stroke risk and potentially lessen reliance on blood-thinning medication. Amulet 360 incorporates design updates intended to improve implant conformity and sealing, while recent clinical-trial data reportedly met safety and effectiveness benchmarks.

Key facts

• Bank of New York Mellon Corp lessened its stake in shares of Abbott Laboratories by 19.7% in the undefined quarter. source
• Abbott concluded the recent trading session at $111.59, a -2.2% move from its prior day's close. source
• The fund owned 9,991,899 shares of Abbott Laboratories after selling 2,450,818 shares during the quarter. source